LeMaitre Vascular, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022
February 24, 2022 at 04:05 pm EST
Share
LeMaitre Vascular, Inc. provided earnings guidance for the first quarter and full year of 2022. For the quarter, the company expects Sales to be $37.7 million - $39.7 million (Mid: $38.7 million, +8%, +10% Org.). EPS to be $0.26 - $0.30. (Mid: $0.28, -1%).
For Full Year, the company expects Sales to be $162 million - $166 million (Mid: $164 million, +6%, +8% Org.). EPS to be $1.35 - $1.45 (Mid: $1.40, +12%).
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Companyâs principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.
LEMAITRE VASCULAR, INC. 
